



ELLEX MEDIA RELEASE

Ellex to Spotlight Evolving Role of SLT for Glaucoma

Adelaide, South Australia, 16 February 2012

Ellex Medical Lasers Limited to Spotlight Evolving Role of SLT for Glaucoma

Ellex Medical Lasers Limited, a manufacturer and distributor of ophthalmic technology for use in the fight against blindness, today announced that it will bring together some of the world's leading SLT practitioners at the Company's SLT Physician Forum during the World Ophthalmology Congress (WOC) in Abu Dhabi, 16 - 20 February 2012.

The forum will center on the evolving role of **SLT (selective laser trabeculoplasty)** for glaucoma treatment, providing participants with the opportunity to share their clinical experience and insight into how to improve the results of SLT in daily clinical practice.

Non-invasive and non-thermal, SLT is an advanced laser therapy which stimulates a natural healing response in the body to manage the elevated intraocular pressure associated with glaucoma. Highly effective, SLT is used as a primary treatment option for the early stages of glaucoma, and can be used in combination with drug therapy or as an alternative therapy when drugs fail. It is a flexible treatment option given that it can be repeated, if necessary, depending on the individual patient's response.

Since the introduction of its SLT technology in 2005, Ellex has been at the forefront of global efforts to raise awareness of the many benefits of SLT – both for physicians and their patients, and for the wider healthcare system.

Forum moderator and leading proponent of SLT, **Prof. Philippe Denis**, MD, PhD, of the University Hospitals of Lyon, France, and President of the French Ophthalmology Society, has successfully performed hundreds of SLT treatments and believes that it is a significant addition to the treatment armamentarium for primary open-angle glaucoma (POAG).

“Along with medications and surgery, SLT has become an important treatment option for glaucoma patients in France. More than 100 clinical centers are now equipped with SLT technology,” commented Prof. Denis.

In addition to its many patient benefits, Prof. Denis believes that it is the treatment's proven clinical efficacy, in which patients can expect to experience a drop in intraocular pressure from 20 to 30 percent (on average) following treatment, that has seen SLT become so widely adopted in the treatment of glaucoma.

“SLT has an excellent safety profile. Because the energy and exposure time of SLT treatment are much lower than ALT and create no harm to the trabecular meshwork (TM), repeat treatments show excellent



ELLEX MEDIA RELEASE

results without compromising the outcome of future surgery, if it is required.”

The Ellex SLT Physician Forum will be held on Saturday, 18 February 2012. A summary of the forum discussion and video interviews with each of the participants will shortly be available for download via the dedicated Ellex SLT website, www.slt-ellex.com.

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 15,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries.

For more Information about Ellex, visit www.ellex.com.

ABOUT SLT FROM ELLEX

Ellex is the global leader in lasers to treat glaucoma, with more than 1500 glaucoma experts outside of the US choosing to rely on SLT from Ellex. Ophthalmologists use our Tango™ and Solo™ SLT lasers to deliver short pulses of low-energy light that trigger the body’s natural healing mechanisms. This process reduces the elevated intraocular pressure (IOP) associated with glaucoma

- The **Tango™ SLT/YAG combination laser** system allows you to instantly switch between SLT and photodisruptor modes at the touch of a button – making procedures as efficient as possible.
- The **Solo™ SLT laser** enables you to provide your glaucoma patients with quick and highly accurate SLT treatment, maximizing treatment options and ensuring effective patient results.

For more information about SLT from Ellex, visit www.slt-ellex.com.

Media enquiries:

Kate Hunt
Ph. 040 4080 679
Email: khunt@ellex.com
Web: www.ellex.com

General enquiries:

Ellex Medical Pty Ltd.
Ph: 08 8104 5200
Email: info@ellex.com
Web: www.ellex.com



ellex.com

Headquarters

82 Gilbert Street
Adelaide, SA, 5000 AUSTRALIA
+61 8 8104 5200

Japan

4-3-7 Miyahara 4F, Yodogawa-ku
Osaka 532-0003 JAPAN
+81 6 6396 2250

USA

7138 Shady Oak Road
Minneapolis, MN, 55344 USA
800 824 7444

Germany

Edisonstraße 20
63512 Hainburg GERMANY
+49 6182 829 6900

Australia

82 Gilbert Street
Adelaide, SA, 5000 AUSTRALIA
+61 8 8104 5264

Europe Support Center

108, avenue Marx Dormoy
63000 Clermont-Ferrand FRANCE
+33 4 73 34 18 55